The efficacy and safety of a branched-chain amino acids granules in the treatment of cirrhotic hypoproteinemia--A multicenter, randomised, control study
- VernacularTitle:复方支链氨基酸颗粒剂治疗肝硬化低蛋白血症多中心临床观察
- Author:
Yaozong YUAN
- Publication Type:Journal Article
- From:
Chinese Journal of Digestion
2001;21(2):102-104
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy and safety of a branched-chain oral amino acids granules (BCAA-G) on the cirrhotic hypoproteinemia. Methods172 patients with cirrhotic hypoproteinemia from 6 hospitals in Shanghai area were studied. BCAA-G and control drug (amino acids capsule) were used respectively for 9 weeks. Symptoms、plasma protein、albumin and Fisher score were evaluated at 4 and 9 weeks to assess the efficacy and safety of BACC-G. ResultsAfter 4 and 9 weeks' therapy, symptoms of two groups improved (P＜ 0.05). Compared with the control group, fatigue was significantly improved (P = 0.03) in BCAA-G group. Plasma protein and albumin increased in BCAA-G group (P = 0.0001). The Fisher score in BCAA-G group improved after 4 weeks ( P = 0. 0005 ) and 9 weeks ( P = 0. 0001 ), while no marked change was found in the control group. The side effect rate was 7.50 % in the BCAA-G group and 3.85 % in the control group, respectively. ConclusionBCAA-G is effective and safe in the treatment of cirrhotic hypoproteinemia.
